Changes in Kidney Function Following Heart Failure Treatment: Focus on Renin-Angiotensin System Blockade

Heart Fail Clin. 2008 Oct;4(4):425-38. doi: 10.1016/j.hfc.2008.03.007.

Abstract

This article begins with a brief overview of the therapeutic agents used in the treatment of heart failure, with a special emphasis on pharmacologic agents that block the renin-angiotensin system (RAS). The discussion then builds upon the basic pathophysiology concepts introduced earlier in this issue to explain how therapies commonly used in heart failure affect kidney function. Against this background, a few of the common clinical dilemmas that clinicians often encounter when treating patients with agents that block the RAS system are discussed.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / adverse effects
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Antihypertensive Agents / adverse effects
  • Antihypertensive Agents / therapeutic use
  • Female
  • Heart Failure / complications*
  • Heart Failure / drug therapy
  • Heart Failure / physiopathology
  • Humans
  • Kidney / blood supply*
  • Kidney / drug effects
  • Kidney / physiopathology
  • Kidney Diseases / etiology*
  • Kidney Diseases / physiopathology
  • Middle Aged
  • Renin-Angiotensin System / drug effects*

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents